Ellis Levine

Medical Oncology
Buffalo Spree Top Doctor 2024

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2024

Cancers Treated:

Research Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine


Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program


Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA


  • University of Minnesota, Minneapolis, MN


  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2023 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

Alaklabi S, Roy AM, Attwood K, George A, O'Connor T, Early A, Levine EG, Gandhi S. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Front Oncol. 2022 Oct 20;12:1012391. doi: 10.3389/fonc.2022.1012391. PMID: 36338738; PMCID: PMC9631302.

Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood KM, Groman A, Williams l, Tarquini ML, Wallace PK, Soh KT, Minderman H, Mcguire O, O’Connor TL, Early AP, Levine EG, Kalinski P (2022) Systemic IFN-a/TLR3-Ligand Combination Reprograms Local Microenvironments of Breast Cancer Lesions for Selective CTL Influx. Journal for ImmunoTherapy of Cancer 2023;11:e007381. doi: 10.1136/jitc-2023-007381

Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023 Jan 6;9(1):1. doi: 10.1038/s41523-022-00504-z. PMID: 36609389; PMCID: PMC9822956.

Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG. Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb;67:89-93. doi: 10.1016/j.breast.2023.01.004. Epub 2023 Jan 17. PMID: 36681001.

Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0. PMID: 37704753; PMCID: PMC10499925.

Witkiewicz AK, Wang J, Schultz E, O’Connor TN, O’Connor T, Levine E, Knudsen E. Developing Algorithms to Predict the Duration of Response to CDK 4/6 Inhibitor-Based Therapy in Metastatic HR+/HER2- Breast Cancer. submitted